Search research articles
Contact Us
Filters
Showing results (61-70 of 80) with videos related to
Page
of 8
Sort By:
Cancer Research
|
September 1, 1986
Prediction of the optimal timing of bone marrow reinfusion after high dose chemotherapy
J P Eder, R C Bast, W P Peters, et al.
Cancer Treatment Reports
|
November 1, 1987
Pharmacokinetics of continuous-infusion high-dose thiotepa
W D Henner, T C Shea, E A Furlong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1989
A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support
T C Shea, M Flaherty, A Elias, et al.
Head & Neck
|
August 15, 2000
Genetic polymorphisms in head and neck cancer risk
J E McWilliams, A J Evans, T M Beer, et al.
Cancer Research
|
November 15, 1989
Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance
Y Y Wang, B A Teicher, T C Shea, et al.
Cancer Research
|
November 1, 1990
Glutathione transferase activity and isoenzyme composition in primary human breast cancers
T C Shea, G Claflin, K E Comstock, et al.
Cancer Research
|
July 1, 1988
Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia
A M Deffie, T Alam, C Seneviratne, et al.
Cancer Research
|
January 15, 1987
Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II)
B A Teicher, S A Holden, M J Kelley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1986
High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer
J P Eder, K Antman, W Peters, et al.
Cancer Treatment Reports
|
February 1, 1987
High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience
K Antman, J P Eder, A Elias, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 80) with videos related to
Sort By:
Page
of 8
Cancer Research
|
September 1, 1986
Prediction of the optimal timing of bone marrow reinfusion after high dose chemotherapy
J P Eder, R C Bast, W P Peters, et al.
Cancer Treatment Reports
|
November 1, 1987
Pharmacokinetics of continuous-infusion high-dose thiotepa
W D Henner, T C Shea, E A Furlong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1989
A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support
T C Shea, M Flaherty, A Elias, et al.
Head & Neck
|
August 15, 2000
Genetic polymorphisms in head and neck cancer risk
J E McWilliams, A J Evans, T M Beer, et al.
Cancer Research
|
November 15, 1989
Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance
Y Y Wang, B A Teicher, T C Shea, et al.
Cancer Research
|
November 1, 1990
Glutathione transferase activity and isoenzyme composition in primary human breast cancers
T C Shea, G Claflin, K E Comstock, et al.
Cancer Research
|
July 1, 1988
Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia
A M Deffie, T Alam, C Seneviratne, et al.
Cancer Research
|
January 15, 1987
Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II)
B A Teicher, S A Holden, M J Kelley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1986
High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer
J P Eder, K Antman, W Peters, et al.
Cancer Treatment Reports
|
February 1, 1987
High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience
K Antman, J P Eder, A Elias, et al.
Page
of 8